This paper was originally published by J. Javier Hernandez, Michael Pryszlak, Lindsay Smith, Connor Yanchus, Naheed Kurji, Vijay M. Shahani and Steven V. Molinski in Front. Oncol., 14 November 2017 under a …
The post Giving Drugs a Second Chance: Overc…
Litigation related to drug patents, whether it be direct patent challenges, contract disputes, or other cases, can provide direct intelligence (through disclosures of competitive intelligence) or indirect intelligence through exposure…
The post Improve…
Disclosure: the majority of the companies mentioned below are, or have been, clients of DrugPatentWatch Drug patent litigation can be used for many aspect of biopharmaceutical business strategy. Many parties…
The post Gain Intelligence on Royalties, Se…
Pharmacists, as the interface between the general public and prescription drug manufacturers, can sometimes feel as if they’re treading a fine line between fulfilling their obligations to pharmaceutical companies and…
The post How Pharmacists Are Trapp…
How Pharmacists Are Trapped in the Middle of Drug Price Wars Read Post »
Which Company Will be the First to Launch a Generic Drug? There are many reasons to find out which companies will be first to launch generic drugs. Payers need to…
The post How to Use Tentative Drug Approvals to Anticipate Generic Entry appeared first …
How to Use Tentative Drug Approvals to Anticipate Generic Entry Read Post »
Which Company Will be the First to Launch a Generic Drug? There are many reasons to find out which companies will be first to launch generic drugs. Payers need to…
The post How to Use Tentative Drug Approvals to Anticipate Generic Entry appeared first …
How to Use Tentative Drug Approvals to Anticipate Generic Entry Read Post »
This paper was originally published by Rishi J Desai, Ameet Sarpatwari, Sara Dejene, Nazleen F Khan, Joyce Lii, James R Rogers, Sarah K Dutcher, Saeid Raofi, Justin Bohn, John Connolly, Michael A Fischer, Aaron S Kesselheim, and Joshua J Gagne in BMJ 2…
This paper was originally published by Martin Schiestl, Markus Zabransky, and Fritz Sörgel in Drug Des Devel Ther. 2017; 11: 1509–1515 under a Creative Commons Attribution – Non Commercial (unported, v3.0) License. Abstract…
The post Ten years of biosi…
Ten years of biosimilars in Europe: development and evolution of the regulatory pathways Read Post »
What can we build for you? Do you have special business intelligence needs? Let us apply our industry expertise and the strength of the DrugPatentWatch platform to develop a solution…
The post Make better decisions with advanced biopharmaceutical busin…
Make better decisions with advanced biopharmaceutical business intelligence Read Post »
Joseph E Stiglitz, American economist and professor at Columbia University, states that prizes should be favored over patents to reward and stimulate innovation. The uniqueness of the patent system referred…
The post Driving Innovation: Drug Patents vs…
Get new actionable insights and updates from BiotechBlog
